Drug Profile
Research programme: phosphodiesterase IV inhibitors - Zambon
Alternative Names: PDE4 inhibitors research programme - Zambon; Phosphodiesterase IV inhibitors research programme - Zambon; Research programme: PDE4 inhibitors - ZambonLatest Information Update: 16 Sep 2005
Price :
$50
*
At a glance
- Originator Zambon Group SpA
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 29 Jul 2004 Preclinical trials in Chronic obstructive pulmonary disease in Europe (PO)